| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,283,572 | 3 | 100 |
| Morris Shannon | Chief Medical Officer | 0 | $0 | 1 | $300,760 | $-300,760 |
| Garner Ebun | General Counsel & Corp. Sec. | 0 | $0 | 2 | $1.98M | $-1.98M |
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is …
Over the last 12 months, insiders at Erasca, Inc. have bought $0 and sold $2.28M worth of Erasca, Inc. stock.
On average, over the past 5 years, insiders at Erasca, Inc. have bought $3.62M and sold $2.28M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 80,000 shares for transaction amount of $181,920 was made by Casdin Alexander W. (director) on 2024‑05‑21.
| 2026-04-01 | Sale | Garner Ebun | Chief Legal Officer | 80,000 0.0254% | $16.40 | $1.31M | -6.33% | |
| 2026-03-04 | Sale | Morris Shannon | Chief Medical Officer | 20,000 0.0064% | $15.04 | $300,760 | +2.25% | |
| 2026-01-07 | Sale | Garner Ebun | General Counsel & Corp. Sec. | 120,000 0.0604% | $5.59 | $670,812 | +185.69% | |
| 2024-05-21 | Casdin Alexander W. | director | 80,000 0.0447% | $2.27 | $181,920 | +7.23% | ||
| 2023-12-06 | Lim Jonathan E | Chairman & CEO | 278,150 0.1825% | $1.72 | $478,418 | +35.84% | ||
| 2023-12-06 | Start Valerie Denise Harding | director | 10,000 0.007% | $1.85 | $18,480 | +35.84% | ||
| 2023-12-05 | Lim Jonathan E | Chairman & CEO | 721,850 0.4606% | $1.69 | $1.22M | +34.29% | ||
| 2023-12-04 | Casdin Alexander W. | director | 30,000 0.0197% | $1.66 | $49,785 | +39.88% | ||
| 2023-10-05 | Lim Jonathan E | Chairman & CEO | 1M 0.695% | $2.03 | $2.03M | +4.25% | ||
| 2023-06-08 | Lim Jonathan E | Chairman & CEO | 100,000 0.0676% | $2.75 | $275,000 | -18.38% | ||
| 2023-04-10 | Casdin Alexander W. | director | 20,000 0.0135% | $2.76 | $55,230 | -14.44% | ||
| 2023-03-28 | Lim Jonathan E | Chairman & CEO | 100,000 0.0693% | $2.84 | $284,000 | -12.41% | ||
| 2023-01-10 | Lim Jonathan E | Chairman & CEO | 60,000 0.0413% | $3.86 | $231,420 | -29.33% | ||
| 2022-12-21 | Bristol James Arthur | director | 20,000 0.0162% | $4.14 | $82,800 | -35.48% | ||
| 2022-12-21 | Start Valerie Denise Harding | director | 10,000 0.0091% | $4.64 | $46,400 | -35.48% | ||
| 2022-12-15 | Casdin Alexander W. | director | 20,000 0.0167% | $4.87 | $97,490 | -42.77% | ||
| 2022-12-14 | Lim Jonathan E | Chairman & CEO | 40,000 0.0338% | $4.99 | $199,600 | -43.49% | ||
| 2022-12-13 | Chen Bihua | director | 307,692 0.3325% | $6.50 | $2M | -44.42% | ||
| 2021-08-10 | Chen Bihua | director | 200,000 0.2202% | $22.10 | $4.42M | -41.38% | ||
| 2021-07-26 | Sale | Chen Bihua | director | 200,000 0.2009% | $18.77 | $3.75M | -35.23% |
| Garner Ebun | Chief Legal Officer | 25076 0.0072% | $367,112.64 | 1 | 2 | <0.0001% |
| Lim Jonathan E | Chairman & CEO | 12899360 3.688% | $188.85M | 7 | 0 | <0.0001% |
| Chen Bihua | director | 10813246 3.0916% | $158.31M | 3 | 1 | <0.0001% |
| Casdin Alexander W. | director | 573974 0.1641% | $8.4M | 4 | 0 | <0.0001% |
| Multani Pratik S | director | 172866 0.0494% | $2.53M | 1 | 0 | <0.0001% |
| Start Valerie Denise Harding | director | 20000 0.0057% | $292,800.00 | 3 | 0 | <0.0001% |
| Bristol James Arthur | director | 20000 0.0057% | $292,800.00 | 1 | 0 | <0.0001% |
| Hambleton Julie | director | 6000 0.0017% | $87,840.00 | 1 | 0 | <0.0001% |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 78 | +49.68% | 17M | +7.89% |
| Decreased Positions | 63 | -40.13% | 13M | -5.83% |
| New Positions | 32 | New | 9M | New |
| Sold Out Positions | 17 | Sold Out | 2M | Sold Out |
| Total Postitions | 172 | +9.55% | 219M | +2.06% |
| Frazier Life Sciences Management, L.P. | $81,599.00 | 8% | 22.73M | 0 | 0% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $72,633.00 | 7.12% | 20.23M | -100,255 | -0.49% | 2025-09-30 |
| Vr Adviser, Llc | $64,107.00 | 6.29% | 17.86M | 0 | 0% | 2025-09-30 |
| Logos Global Management Lp | $54,389.00 | 5.34% | 15.15M | +150,000 | +1% | 2025-09-30 |
| Blackrock, Inc. | $54,106.00 | 5.31% | 15.07M | -94,879 | -0.63% | 2025-09-30 |
| Suvretta Capital Management, Llc | $52,062.00 | 5.11% | 14.5M | 0 | 0% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $48,680.00 | 4.78% | 13.56M | +2M | +13.88% | 2025-09-30 |
| Vanguard Group Inc | $45,994.00 | 4.51% | 12.81M | +116,235 | +0.92% | 2025-09-30 |
| Arch Venture Management, Llc | $39,689.00 | 3.89% | 11.06M | 0 | 0% | 2025-09-30 |
| Vivo Capital, Llc | $33,292.00 | 3.27% | 9.27M | +3M | +37.25% | 2025-09-30 |